Matches in Wikidata for { <http://www.wikidata.org/entity/Q56516518> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q56516518 description "article scientifique publié en 2018" @default.
- Q56516518 description "im August 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q56516518 description "wetenschappelijk artikel" @default.
- Q56516518 description "наукова стаття, опублікована в серпні 2018" @default.
- Q56516518 name "Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer" @default.
- Q56516518 name "Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer" @default.
- Q56516518 type Item @default.
- Q56516518 label "Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer" @default.
- Q56516518 label "Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer" @default.
- Q56516518 prefLabel "Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer" @default.
- Q56516518 prefLabel "Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer" @default.
- Q56516518 P1433 Q56516518-E5B549D3-ABE7-481D-9399-FE3F426D071D @default.
- Q56516518 P1476 Q56516518-B062787A-9A8A-4100-9582-DA1E4D030C8D @default.
- Q56516518 P2093 Q56516518-0AC42F25-C94F-46BC-865B-A9F9BA73BD1D @default.
- Q56516518 P2093 Q56516518-3272C214-2BB6-48BB-AEE8-D47AECD7D464 @default.
- Q56516518 P2093 Q56516518-3D0258EC-CAE9-4101-8A55-B35D4665C291 @default.
- Q56516518 P2093 Q56516518-558D5DE7-951C-4870-AF70-3C25A7C6F0C8 @default.
- Q56516518 P2093 Q56516518-5A3FD213-DEAD-44A1-AFAF-CC59AF4C0E4B @default.
- Q56516518 P2093 Q56516518-691CABB4-B826-4877-860C-C482F6E43874 @default.
- Q56516518 P2093 Q56516518-71224341-3927-4D89-BFA0-22A6D7A780A2 @default.
- Q56516518 P2093 Q56516518-749592BB-BD88-4AA8-8657-307C811A65F4 @default.
- Q56516518 P2093 Q56516518-8C8A5496-7C9F-41DD-BB8A-843C882EC814 @default.
- Q56516518 P2093 Q56516518-FF4C186E-F0CA-423D-ACB7-DCC35BC8BABA @default.
- Q56516518 P304 Q56516518-E347D007-E959-4738-96C6-C6028598BECA @default.
- Q56516518 P31 Q56516518-EB03086F-827B-41E6-A417-C0C45327D5B9 @default.
- Q56516518 P356 Q56516518-13B38912-7F25-4DDF-B751-2C1C9EFAE963 @default.
- Q56516518 P407 Q56516518-0AF9DB24-ED82-4A11-B89E-5700C536635A @default.
- Q56516518 P433 Q56516518-1426A6A4-37BF-4A58-B558-F0D286752C43 @default.
- Q56516518 P478 Q56516518-871EEA47-FC79-4365-BD46-E025235D1C90 @default.
- Q56516518 P50 Q56516518-64881AC3-AF40-4986-8A1A-3702CC2B66D8 @default.
- Q56516518 P577 Q56516518-73877E0E-52C5-4CF0-B361-D963A8CC1E45 @default.
- Q56516518 P698 Q56516518-3C55811C-93D3-4D51-B918-647ACFE3F302 @default.
- Q56516518 P921 Q56516518-03D7130E-E73F-4C82-BF42-8B4AC8B8B01B @default.
- Q56516518 P921 Q56516518-3FD70D9A-F47F-4431-8768-006B86610502 @default.
- Q56516518 P921 Q56516518-4B6F9FE8-B58C-4077-9F37-F1056FEFA3A7 @default.
- Q56516518 P921 Q56516518-7B1E457D-E43E-4974-8E11-1BF60F536F82 @default.
- Q56516518 P921 Q56516518-878498BA-65F2-48B1-AEDD-778865A92513 @default.
- Q56516518 P921 Q56516518-E26BFE76-86CB-4B07-BFD3-1EED753B5A56 @default.
- Q56516518 P356 J.CLBC.2018.01.010 @default.
- Q56516518 P698 29486983 @default.
- Q56516518 P1433 Q332245 @default.
- Q56516518 P1476 "Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer" @default.
- Q56516518 P2093 "Aaron Goldhirsch" @default.
- Q56516518 P2093 "Antonella Palazzo" @default.
- Q56516518 P2093 "Emilia Montagna" @default.
- Q56516518 P2093 "Giuseppe Cancello" @default.
- Q56516518 P2093 "Manuelita Mazza" @default.
- Q56516518 P2093 "Marco Colleoni" @default.
- Q56516518 P2093 "Monica Iorfida" @default.
- Q56516518 P2093 "Raffaella Ghisini" @default.
- Q56516518 P2093 "Silvia Dellapasqua" @default.
- Q56516518 P2093 "Vincenzo Bagnardi" @default.
- Q56516518 P304 "328-335" @default.
- Q56516518 P31 Q13442814 @default.
- Q56516518 P356 "10.1016/J.CLBC.2018.01.010" @default.
- Q56516518 P407 Q1860 @default.
- Q56516518 P433 "4" @default.
- Q56516518 P478 "18" @default.
- Q56516518 P50 Q56850295 @default.
- Q56516518 P577 "2018-08-01T00:00:00Z" @default.
- Q56516518 P698 "29486983" @default.
- Q56516518 P921 Q412616 @default.
- Q56516518 P921 Q413299 @default.
- Q56516518 P921 Q415588 @default.
- Q56516518 P921 Q423762 @default.
- Q56516518 P921 Q42824440 @default.
- Q56516518 P921 Q5922406 @default.